RESUMEN
We investigated the regulation of beta(2)-adrenergic receptors (beta(2)AR) by protein kinase C (PKC) in rat C6 glioma cells at the levels of receptor activity, protein expression and gene expression. Cells exposed to 4beta-phorbol-12-myristate-13-acetate (PMA), a potent activator of PKC, exhibited a time- and concentration-dependent decrease in beta(2)AR binding activity. Maximum down-regulation was approximately 50% by 24 h and western blot analysis revealed a parallel decrease in beta(2)AR protein. In addition, PMA treatment resulted in an acute desensitization of beta(2)AR-stimulated cyclic AMP response prior to any reduction in receptor levels. PMA exposure also affected steady-state beta(2)AR mRNA levels in a time-dependent, biphasic manner. During the first 4 h, levels decreased by approximately 60% and then slowly recovered to approximately 75% of control by 24 h. As the reduction in receptor mRNA was not due to a decrease in its stability, we examined beta(2)AR gene transcription by nuclear run-on assays. Transcriptional activity in nuclei from C6 cells treated with PMA for 2 h was reduced by 70% compared to controls. Thus PKC can regulate beta(2)AR at least two levels: the first being an acute desensitization of receptor function, and the second being a more prolonged repression of receptor gene transcription that in turn results in decreased receptor expression.
Asunto(s)
Regulación hacia Abajo , Expresión Génica , Glioma/metabolismo , Proteína Quinasa C/metabolismo , Receptores Adrenérgicos beta 2/genética , Animales , Western Blotting , AMP Cíclico/metabolismo , Activación Enzimática/efectos de los fármacos , Cinética , ARN Mensajero/análisis , Ratas , Receptores Adrenérgicos beta 2/análisis , Acetato de Tetradecanoilforbol/farmacología , Transcripción Genética , Células Tumorales CultivadasRESUMEN
PURPOSE: To report a case of neonatal orbital ganglioglioma originating from ectopic neural tissue. METHOD: Case report. RESULTS: An African-American male presented at birth with proptosis and expansion of the left orbit. A discrete soft-tissue mass was located inferolateral to the globe, which proved to be a ganglioglioma. CONCLUSION: The tumor is presumed to have originated from ectopic neural tissue in the orbit. Although infrequent, this tumor should be included in the differential diagnosis of neonatal orbital neoplasms.
Asunto(s)
Encéfalo , Coristoma/patología , Ganglioglioma/patología , Neoplasias Orbitales/patología , Coristoma/diagnóstico por imagen , Coristoma/cirugía , Diagnóstico Diferencial , Exoftalmia/patología , Ganglioglioma/diagnóstico por imagen , Ganglioglioma/cirugía , Humanos , Recién Nacido , Masculino , Neoplasias Orbitales/diagnóstico por imagen , Neoplasias Orbitales/cirugía , Tomografía Computarizada por Rayos XRESUMEN
In the current study, we investigated the mechanism by which protein kinase C (PKC) regulates the expression of beta1-adrenergic receptor (beta1AR) mRNA in rat C6 glioma cells. Exposure of the cells to 4beta-phorbol-12-myristate-13-acetate (PMA), an activator PKC, resulted in a down-regulation of both beta1AR binding sites and mRNA levels in a time- and concentration-dependent manner. This effect was not observed with phorbol esters that do not activate PKC and was blocked by bisindolylmaleimide, a specific PKC inhibitor. Activation of PKC did not reduce the half-life of beta1AR mRNA but significantly decreased the activity of the beta1AR promoter, as determined by reporter analysis. A putative response element, with partial homology to a consensus cAMP response element, was identified by mutation analysis of the promoter at positions -343 to -336, relative to the translational start site. Mutation of this putative regulatory element, referred to as a beta1AR-PKC response element, completely blocked the PKC-mediated down-regulation of beta1AR promoter activity. Gel mobility shift analysis detected two specific bands when C6 cell extracts were incubated with a labeled DNA probe containing the beta1AR-PKC response element sequence. Formation of one of these bands was inhibited by an oligonucleotide probe containing a consensus CRE and disrupted by an antibody for cAMP response element binding protein. Based on these studies, we propose that the PKC-induced down-regulation of beta1AR gene transcription in C6 cells is mediated in part by a cAMP response element binding protein-dependent mechanism acting on a novel response element.
Asunto(s)
Carcinógenos/farmacología , Proteína Quinasa C/metabolismo , ARN Mensajero/efectos de los fármacos , Receptores Adrenérgicos beta 1/efectos de los fármacos , Acetato de Tetradecanoilforbol/farmacología , Animales , AMP Cíclico/metabolismo , Regulación hacia Abajo , Glioma/genética , Glioma/metabolismo , Regiones Promotoras Genéticas/efectos de los fármacos , ARN Mensajero/metabolismo , Ratas , Receptores Adrenérgicos beta 1/genética , Células Tumorales Cultivadas/efectos de los fármacosRESUMEN
The mechanism by which cholera toxin (CT) is internalized from the plasma membrane before its intracellular reduction and subsequent activation of adenylyl cyclase is not well understood. Ganglioside GM1, the receptor for CT, is predominantly clustered in detergent-insoluble glycolipid rafts and in caveolae, noncoated, cholesterol-rich invaginations on the plasma membrane. In this study, we used filipin, a sterol-binding agent that disrupts caveolae and caveolae-like structures, to explore their role in the internalization and activation of CT in CaCo-2 human intestinal epithelial cells. When toxin internalization was quantified, only 33% of surface-bound toxin was internalized by filipin-treated cells within 1 h compared with 79% in untreated cells. However, CT activation as determined by its reduction to form the A1 peptide and CT activity as measured by cyclic AMP accumulation were inhibited in filipin-treated cells. Another sterol-binding agent, 2-hydroxy-beta-cyclodextrin, gave comparable results. The cationic amphiphilic drug chlorpromazine, an inhibitor of clathrin-dependent, receptor-mediated endocytosis, however, affected neither CT internalization, activation, nor activity in contrast to its inhibitory effects on diphtheria toxin cytotoxicity. As filipin did not inhibit the latter, the two drugs appeared to distinguish between caveolae- and coated pit-mediated processes. In addition to its effects in CaCo-2 cells that express low levels of caveolin, filipin also inhibited CT activity in human epidermoid carcinoma A431 and Jurkat T lymphoma cells that are, respectively, rich in or lack caveolin. Thus, filipin inhibition correlated more closely with alterations in the biochemical characteristics of CT-bound membranes due to the interactions of filipin with cholesterol rather than with the expressed levels of caveolin and caveolar structure. Our results indicated that the internalization and activation of CT was dependent on and mediated through cholesterol- and glycolipid-rich microdomains at the plasma membrane rather than through a specific morphological structure and that these glycolipid microdomains have the necessary components required to mediate endocytosis.
Asunto(s)
Toxina del Cólera/farmacología , Toxina del Cólera/farmacocinética , Filipina/farmacología , Mucosa Intestinal/fisiología , Adenilil Ciclasas/metabolismo , Transporte Biológico/efectos de los fármacos , Carcinoma de Células Escamosas , Membrana Celular/fisiología , Membrana Celular/ultraestructura , Clorpromazina/farmacología , Toxina del Cólera/antagonistas & inhibidores , Colesterol/metabolismo , Invaginaciones Cubiertas de la Membrana Celular/fisiología , Neoplasias del Colon , AMP Cíclico/metabolismo , Ciclodextrinas/farmacología , Toxina Diftérica/toxicidad , Endocitosis/efectos de los fármacos , Endocitosis/fisiología , Activación Enzimática , Glucolípidos/metabolismo , Humanos , Imipramina/farmacología , Mucosa Intestinal/efectos de los fármacos , Células Jurkat , Cinética , Lípidos de la Membrana/metabolismo , Células Tumorales CultivadasRESUMEN
Although there is considerable interest in the regulation of the different beta-adrenergic receptor (AR) subtypes, most previous studies have utilized stably transfected cells expressing recombinant receptors under the control of viral promoters. Human SK-N-MC neurotumor cells appear to be novel, since they express both endogenous beta 1AR and beta 3AR based on radioligand binding and on functional response. Saturation binding of either the hydrophilic ligand (-)-[3H]CGP-12177 or the more hydrophobic (-)-[125I]iodocyanopindolol indicated the presence of two populations of binding sites with high and low affinities. With either ligand, the beta 1AR antagonist CGP-20712A preferentially inhibited binding to the high-affinity sites. This is consistent with the latter representing beta 1AR whereas the low-affinity sites represent beta 3AR. Both subtypes appeared to be functional on the basis of isoproterenol stimulation of cyclic adenosine monophosphate (cAMP) in intact cells and adenylyl cyclase activity in cell membranes in the absence and presence of CGP-20712A. SK-N-MC-IXC cells, derived by twice subcloning the parental cells, also expressed both beta AR subtypes, indicating that they co-exist in the same cell. SK-N-MC cells exposed to isoproterenol exhibited a rapid sequestration and a slower downregulation of beta 1AR. The latter subtype also underwent desensitization, as indicated by a rightward shift to less sensitivity in the EC50 for isoproterenol stimulation of adenylyl cyclase activity. In contrast, the beta 3AR subtype was resistant to agonist-mediated sequestration, downregulation, and desensitization. Thus, when endogenously expressed in the same cell line, human beta 1AR and beta 3AR display differences in their ability to be regulated by agonist.
Asunto(s)
Agonistas de Receptores Adrenérgicos beta 1 , Receptores Adrenérgicos beta/metabolismo , Agonistas Adrenérgicos beta/farmacología , Regulación hacia Abajo , Humanos , Ligandos , Tumores Neuroectodérmicos Periféricos Primitivos/patología , Receptores Adrenérgicos beta 1/metabolismo , Receptores Adrenérgicos beta 3 , Tritio/metabolismo , Células Tumorales CultivadasRESUMEN
ICER (inducible cyclic AMP early repressor), a member of the cyclic AMP response element (CRE) modulator (CREM) family of transcription factors, is a powerful repressor of cyclic AMP-mediated transactivation. Our studies characterize the regulation of ICER in C6 glioma cells and investigate its role in repressing transcription of the beta1-adrenergic receptor (beta1AR) gene. Incubation with isoproterenol (100 nM) results in a rapid induction in levels of mRNA for ICER and its splice variant ICERgamma, with maximal induction occurring after 2 h of treatment. Incubation with isoproterenol also increased levels of CREM isoforms within 1 h; this was unexpected given previous reports that these isoforms are not rapidly induced. Increased expression of ICER and CREM was accompanied by induction of two CRE-binding complexes. The presence of ICER in these two CRE-binding complexes is demonstrated by their disruption with CREM antibody and by their comigration with recombinant ICER. Because the time course for isoproterenol induction of ICER mRNA and CRE binding corresponds to that for down-regulation of beta1AR mRNA levels in C6 glioma cells, the influence of ICER beta1AR transcription was directly examined. Coexpression of ICER significantly decreased transcriptional activity of a rat beta1AR promoter-luciferase reporter construct that contains a CRE. In contrast, coexpression of ICER did not influence two truncated rat beta1AR promoter constructs that lack the CRE site. These data demonstrate that ICER can interact at the beta1AR promoter to repress transcription.
Asunto(s)
Proteínas de Unión al ADN/genética , Receptores Adrenérgicos beta 1/genética , Proteínas Represoras/genética , Animales , Secuencia de Bases , Sitios de Unión , Modulador del Elemento de Respuesta al AMP Cíclico , Cartilla de ADN/genética , Proteínas de Unión al ADN/metabolismo , Regulación hacia Abajo , Regulación de la Expresión Génica/efectos de los fármacos , Glioma/genética , Isoproterenol/farmacología , Datos de Secuencia Molecular , Proteínas Nucleares/metabolismo , Regiones Promotoras Genéticas , Ratas , Secuencias Reguladoras de Ácidos Nucleicos , Transcripción Genética , Células Tumorales CultivadasRESUMEN
CGP 12177A originally was developed as a hydrophilic antagonist to detect cell surface beta 1- and beta 2-adrenergic receptors, and subsequently was found to be a partial agonist for the atypical or beta 3-adrenergic receptor. Using hamster cells stably expressing either the human beta 1-, human beta 2- or rat beta 1-adrenergic receptor, we found that CGP 12177A behaved as an agonist of beta 1-adrenergic receptors. Whereas at low concentrations, CGP 12177a behaved as an antagonist and inhibited isoproterenol stimulation of adenylyl cyclase activity, at higher concentrations, it stimulated a response even in the absence of isoproterenol. The agonistic properties of CGP 12177A were positively correlated with the level of beta 1-adrenergic receptor expression. Thus, at low receptor of densities, CGP 12177A behaved as a weak, partial agonist whereas as high receptor densities, the drug was a full agonist. At similar high densities of the beta 2-adrenergic receptor, CGP 12177A acted only as a partial agonist. Competition binding studies to membranes from cells expressing beta 1-adrenergic receptors indicated that approximately 90% of the receptors were in a high affinity, guanine nucleotide-insensitive state for CGP 12177A whereas approximately 10% of the receptors were in a lower affinity, guanine nucleotide-sensitive state for CGP 12177A. We propose that the latter receptors are precoupled to stimulatory G proteins and recognize CGP 12177A as an agonist whereas the high affinity, uncoupled receptors recognize CGP 12177A as an antagonist.
Asunto(s)
Agonistas Adrenérgicos beta/farmacología , Antagonistas Adrenérgicos beta/farmacología , Propanolaminas/farmacología , Receptores Adrenérgicos beta/metabolismo , 1-Metil-3-Isobutilxantina/farmacología , Adenilil Ciclasas/metabolismo , Animales , Línea Celular , Membrana Celular/efectos de los fármacos , Membrana Celular/metabolismo , Colforsina/farmacología , Cricetinae , AMP Cíclico/metabolismo , Relación Dosis-Respuesta a Droga , Proteínas de Unión al GTP/metabolismo , Humanos , Isoproterenol/farmacología , Propanolaminas/administración & dosificación , Propranolol/farmacología , Ratas , Receptores Adrenérgicos beta/efectos de los fármacos , Estereoisomerismo , Transfección , Zinc/farmacologíaRESUMEN
Incubation of rat C6 glioma cells with beta-adrenergic receptor (beta AR) agonist or with agents that increase cAMP levels results in down-regulation of the beta 2AR, as measured by the loss of radioligand binding sites. In the present study, the role of beta 2AR mRNA expression and stability in the down-regulation of beta 2AR sites in C6 cells was examined. Isoproterenol or forskolin treatment decreased beta 2AR mRNA levels in a time-dependent manner, with maximal loss of approximately 50% being observed after 2 hr. Pretreatment of the cells with a potent protein synthesis inhibitor, Pseudomonas exotoxin A, completely blocked isoproterenol- and forskolin-mediated down-regulation of beta 2AR mRNA. Exposure to agonist did not significantly influence the half-life of beta 2AR mRNA, which was approximately 60 min. In contrast, isoproterenol treatment for 2 hr significantly decreased the rate of beta 2AR gene transcription, as determined by nuclear run-on analysis. Based on these results, we propose that agonist regulation of beta 2AR mRNA in C6 cells is mediated by activation of the cAMP system and occurs at the level of beta 2AR gene transcription, not mRNA stability. In addition, the observed requirement for protein synthesis indicates that down-regulation of beta 2AR mRNA may be mediated by expression of a repressor of beta 2AR gene transcription.
Asunto(s)
ADP Ribosa Transferasas , Toxinas Bacterianas , Colforsina/farmacología , Isoproterenol/farmacología , Inhibidores de la Síntesis de la Proteína/farmacología , Receptores Adrenérgicos beta 2/genética , Transcripción Genética/efectos de los fármacos , Factores de Virulencia , Agonistas de Receptores Adrenérgicos beta 2 , Animales , Secuencia de Bases , Cartilla de ADN , Regulación hacia Abajo , Exotoxinas/farmacología , Datos de Secuencia Molecular , Pseudomonas , ARN Mensajero/genética , ARN Mensajero/metabolismo , Ratas , Células Tumorales Cultivadas , Exotoxina A de Pseudomonas aeruginosaRESUMEN
It is well-established that agonist-mediated desensitization of the beta 2-adrenergic receptor (beta 2AR) involves its phosphorylation by protein kinase A (PKA) and the beta AR kinase (beta ARK). The phosphorylated receptor is less efficient at mediating agonist stimulation of adenylyl cyclase activity. The result is an increase in the concentration of agonist required for half-maximal stimulation (EC50) and a reduction in maximal stimulation (Vmax). As less is known about desentization of the human beta 1 AR, we compared the desensitization pattern of human beta 1 AR and beta 2AR stably expressed in two different hamster cell lines: Chinese hamster ovary (CHO), and Chinese hamster fibroblast (CHW). Following agonist treatment, all of the cell lines exhibited an increase in EC50, and a reduction in Vmax was observed in CHO-beta 2 but not beta 1 cells. CHW-beta 1 cells were resistant to acute agonist-mediated reduction in Vmax compared to CHW-beta 2 cells. More prolonged agonist exposure produced a modest reduction in Vmax and this effect was more noticeable when the CHW cells expressed lower levels of beta 1AR. To explore the role of protein kinases in these effects, digitonin-permeabilized CHW cells were loaded either with heparin (a beta ARK inhibitor) or a peptide inhibitor of PKA and exposed to agonist. In both beta 2AR- and beta 1AR-expressing cells, heparin inhibited the reduction in Vmax and the PKA inhibitor blocked the increase in EC50. Finally, exposing CHW cells expressing either subtype to a permeable cyclic AMP derivative caused an increase in EC50 similar to that observed in agonist-treated cells, but without any reduction in maximal activity. Our data suggest that whereas PKA-mediated desensitization is not subtype-specific, human beta 1AR is more resistant to beta ARK-mediated desensitization compared to the human beta 2AR.
Asunto(s)
Adenilil Ciclasas/metabolismo , Isoproterenol/farmacología , Receptores Adrenérgicos beta 1/fisiología , Receptores Adrenérgicos beta 2/fisiología , Animales , Células CHO , Línea Celular , Permeabilidad de la Membrana Celular , Cricetinae , Cricetulus , Proteínas Quinasas Dependientes de AMP Cíclico/antagonistas & inhibidores , Proteínas Quinasas Dependientes de AMP Cíclico/metabolismo , Relación Dosis-Respuesta a Droga , Regulación hacia Abajo , Fibroblastos , Heparina/farmacología , Humanos , Cinética , Inhibidores de Proteínas Quinasas , Proteínas Quinasas/metabolismo , Receptores Adrenérgicos beta 1/biosíntesis , Receptores Adrenérgicos beta 2/biosíntesis , Proteínas Recombinantes/biosíntesis , Proteínas Recombinantes/metabolismo , TransfecciónRESUMEN
The E. coli type I heat-labile enterotoxin (LT-I) shares considerable functional, structural, and immunological homology with cholera toxin (CT). Although the ganglioside GM1 is the sole receptor for CT, LT-I also appears to utilize additional, unique receptors on intestinal cells not recognized by CT. We characterized this second class of LT-I receptors using the human intestinal epithelial cell line, CaCo-2. CaCo-2 cells bound 8-fold more LT-I than CT, and some of these additional LT-I receptors appeared to be functional, as CT-B only partially inhibited LT-I activity at concentrations that completely inhibited CT activity. Membranes from unlabeled or [3H]galactose-labeled cells were incubated with toxin B subunits and extracted with Triton X-100, and the solubilized toxin B-receptor complexes were immunoabsorbed with anti-B bound to protein A-Sepharose. When organic extracts of the complexes were separated by thin-layer chromatography and overlayed with [125I]toxin, both toxins were found to bind only GM1. Separation of the complexes from [3H]galactose-labeled membranes by sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed a series of galactoproteins specifically recognized by LT-I but not by CT. Similar proteins were detected on Western blots probed with [125I]toxin. LT-I activity on intact cells and binding to membranes and the above galactoproteins were enhanced by neuraminidase treatment even in the presence of CT-B. beta-1,4-Galactosidase and endo-beta-1,4-galactosidase, but not beta-1,3-galactosidase, significantly reduced LT-I binding. LT-I binding to fetuin and transferrin exhibited a similar glycosidase sensitivity.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Amino Azúcares/análisis , Toxinas Bacterianas/metabolismo , Enterotoxinas/metabolismo , Proteínas de Escherichia coli , Escherichia coli , Guanilato Ciclasa/metabolismo , Mucosa Intestinal/metabolismo , Polisacáridos/análisis , Receptores de Péptidos/metabolismo , Toxinas Bacterianas/farmacología , Línea Celular , Membrana Celular/metabolismo , Toxina del Cólera/metabolismo , Toxina del Cólera/farmacología , AMP Cíclico/metabolismo , Enterotoxinas/farmacología , Epitelio/metabolismo , Gangliósido G(M1)/metabolismo , Galactosidasas/farmacología , Glicoproteínas/metabolismo , Guanilato Ciclasa/análisis , Humanos , Receptores de Enterotoxina , Receptores Acoplados a la Guanilato-Ciclasa , Receptores de Péptidos/análisisRESUMEN
Exposure of rat C6 glioma cells to either agonists or agents that increase cyclic AMP levels leads to down-regulation of beta 1-adrenergic receptors (beta 1 AR) as measured by loss of radioligand binding sites. The present study examines the influence of isoproterenol and forskolin treatment on levels of beta 1 AR mRNA, mRNA stability, and gene transcription rate. Isoproterenol treatment of C6 cells altered beta 1 AR mRNA levels in a biphasic manner; i.e., short-term exposure (30-60 min) increased by 50%, whereas longer exposure (2-6 h) decreased by 50% the levels of beta 1 AR mRNA. The extent of both the up- and down-regulation was dependent on agonist concentration. Similar regulation of beta 1 AR mRNA was observed in forskolin-treated cells. Pretreatment of the cells with Pseudomonas exotoxin A, a potent inhibitor of protein synthesis, completely blocked isoproterenol- and forskolin-mediated down-regulation of beta 1 AR mRNA, and thereby potentiated the increase in receptor mRNA up to fourfold over the 6-h time course. The mechanisms underlying beta 1 AR mRNA down-regulation were examined. The half-life of beta 1 AR mRNA was slightly increased (from 61 to 77 min) after a 2-h exposure of the cells to either isoproterenol or forskolin. Nuclear run-on analysis demonstrated that the rate of beta 1 AR gene transcription was increased after isoproterenol incubation for 60 min, but then decreased after 90-240 min, consistent with the time course for up- and down-regulation of beta 1 AR mRNA. Isoproterenol treatment (120 min) also decreased the level of beta 1 AR nascent transcripts, purified by affinity chromatography of RNA isolated from 4-thiouridine-pulsed cells. The results demonstrate that beta 1 AR mRNA has a relatively short half-life and that agonist regulation of beta 1 AR mRNA is mediated by activation of the cyclic AMP system. Moreover, the results indicate that agonist regulation of beta 1 AR mRNA occurs at the level of beta 1 AR gene transcription, not mRNA stability. Finally, the observed requirement for protein synthesis indicates that beta 1 AR mRNA down-regulation may be mediated by the induction of a repressor of the beta 1 AR gene.
Asunto(s)
Agonistas de Receptores Adrenérgicos beta 1 , Colforsina/farmacología , AMP Cíclico/agonistas , AMP Cíclico/farmacología , Glioma/genética , Glioma/patología , Isoproterenol/farmacología , ARN Mensajero/genética , Receptores Adrenérgicos beta 1/genética , Transcripción Genética , Animales , AMP Cíclico/fisiología , Regulación hacia Abajo , Endotoxinas/farmacología , Glioma/metabolismo , ARN Mensajero/análisis , ARN Mensajero/metabolismo , Ratas , Receptores Adrenérgicos beta 1/fisiología , Factores de Tiempo , Células Tumorales CultivadasRESUMEN
Exposure of human SK-N-MC neurotumor cells to 4 beta-phorbol 12-myristate 13-acetate (PMA) increased isoproterenol stimulation of cyclic AMP levels by severalfold. This potentiation was blocked by inhibitors of protein kinase C (PKC) and did not occur in cells in which PKC had been down-regulated. PMA treatment also enhanced the stimulation by dopamine, cholera toxin, and forskolin. Thus, the effect of PMA on the adenylylcyclase system was postreceptor and involved either the guanine nucleotide binding regulatory (G) proteins or the cyclase itself. As PMA treatment did not impair the inhibition of isoproterenol stimulation by neuropeptide Y, an involvement of the inhibitory G protein Gi was unlikely. Cholate extracts of membranes from control and PMA-treated cells were equally effective in the reconstitution of adenylylcyclase activity in S49 cyc- membranes, which lack the stimulatory G protein subunit Gs alpha; thus, Gs did not appear to be the target of PMA action. Membranes from PMA-treated cells exhibited increased adenylylcyclase activity to all stimulators including Mn2+ and Mn2+ plus forskolin. In addition, activity was increased when control membranes were incubated with ATP and purified PKC from rat brain. This is consistent with a direct effect of PKC on the adenylylcyclase catalyst in SK-N-MC cells. PMA treatment also resulted in a shift to less sensitivity in the K(act) for isoproterenol but not for dopamine or CGP-12177 (a beta 3-adrenergic agonist) stimulation. Thus, the beta 1 but not the D1 or beta 3 receptors were being desensitized by PKC activation. Analysis of SK-N-MC cells by western blotting with antibodies against different PKC isozymes revealed that both the alpha and zeta isozymes were present in these cells. Whereas PKC-alpha was activated and translocated from cytosol to membrane by phorbol esters, the zeta isozyme was not. Thus, PKC-alpha, which has been implicated in desensitization in other cell lines, also appears to potentiate adenylylcyclase activity.
Asunto(s)
Adenilil Ciclasas/metabolismo , AMP Cíclico/metabolismo , Isoenzimas/metabolismo , Isoproterenol/farmacología , Proteína Quinasa C/metabolismo , Acetato de Tetradecanoilforbol/farmacología , Antagonistas Adrenérgicos beta/farmacología , Alcaloides/farmacología , Compuestos de Aluminio/farmacología , Animales , Encéfalo/enzimología , Línea Celular , Membrana Celular/metabolismo , Toxina del Cólera/farmacología , Colforsina/farmacología , Dopamina/farmacología , Sinergismo Farmacológico , Fluoruros/farmacología , Proteínas de Unión al GTP/metabolismo , Humanos , Cinética , Manganeso/farmacología , Neuroblastoma , Neuropéptido Y/farmacología , Propanolaminas/farmacología , Proteína Quinasa C/antagonistas & inhibidores , Ratas , Esfingosina/farmacología , Estaurosporina , Células Tumorales CultivadasRESUMEN
Rat C6 glioma cells have both beta 1- and beta 2-adrenergic receptors in approximately 7:3 ratio. When the cells were exposed to the beta-adrenergic agonist isoproterenol, there was a rapid sequestration of up to 50% of the surface receptor population over a 30-min period as measured by the loss of binding of the hydrophilic ligand [3H] CGP-12177 to intact cells. Using the beta 1-selective antagonist CGP 20712A to quantify the proportion of the two subtypes, it was found that although both beta 1 and beta 2 receptors were sequestered, the latter were sequestered initially twice as fast as the former. More prolonged agonist exposure led to a down-regulation of approximately 90% of the total receptor population by 6 h as measured by the loss of binding of the more hydrophobic ligand [125I]iodocyanopindolol to cell lysates. The two subtypes, however, underwent down-regulation with similar kinetics. Treatment of the cells with agents that raise cyclic AMP levels such as cholera toxin and forskolin resulted in a slower, but still coordinated down-regulation of both subtypes. Thus, there appears to be both independent and coordinate regulation of endogenous beta 1-and beta 2-adrenergic receptors in the same cell line.
Asunto(s)
Glioma/metabolismo , Receptores Adrenérgicos beta 1/metabolismo , Receptores Adrenérgicos beta 2/metabolismo , Animales , Astrocitos/efectos de los fármacos , Astrocitos/metabolismo , Diferenciación Celular/efectos de los fármacos , Toxina del Cólera/farmacología , Colforsina/farmacología , AMP Cíclico/metabolismo , Regulación hacia Abajo/efectos de los fármacos , Regulación hacia Abajo/fisiología , Isoproterenol/farmacología , Oligodendroglía/efectos de los fármacos , Oligodendroglía/metabolismo , Ratas , Receptores Adrenérgicos beta 1/efectos de los fármacos , Receptores Adrenérgicos beta 2/efectos de los fármacos , Células Tumorales CultivadasRESUMEN
HeLa cells express low levels of beta-adrenergic receptor (beta AR) of the beta 2-subtype. When exposed to sodium butyrate, receptor levels increased up to 4-fold in a time dependent manner, reaching a maximum after 12 to 15 h of treatment. Sodium butyrate treatment also caused a 3 to 4 fold increase in levels of beta 2AR mRNA determined by hybridization blot analysis. The induction of beta 2AR mRNA temporally preceded the increase in receptor binding activity, reaching a maximum after 4 to 6 h of treatment, and remaining elevated for up to 24 h. Prior exposure of the cells to the protein synthesis inhibitor cycloheximide prevented the butyrate-induced increase in receptor binding but had no effect on the increase in receptor mRNA. Blocking DNA synthesis and cell growth by excess thymidine did not increase beta 2AR mRNA or binding or prevent the effects of sodium butyrate. Thus, butyrate appears to induce beta 2AR mRNA by a mechanism independent of DNA and protein synthesis.
Asunto(s)
Butiratos/farmacología , ARN Mensajero/biosíntesis , Receptores Adrenérgicos beta/genética , Ácido Butírico , Células HeLa , Humanos , Proteínas de Neoplasias/biosíntesis , Ensayo de Unión Radioligante , Receptores Adrenérgicos beta/efectos de los fármacos , Receptores Adrenérgicos beta/metabolismoRESUMEN
Cholera toxin (CT) consists of a pentameric B subunit that binds to specific cell surface receptors identified as ganglioside GM1 and an A subunit that activates adenylylcyclase. The A subunit consists of A1 and A2 peptides linked by a disulfide bond; A2 acts to connect A to B, whereas A1 is an ADP-ribosyltransferase that modifies the alpha subunit of the stimulatory G protein (Gs). How the toxin is oriented when it binds to the cell surface and the related issue of the mechanism by which A1 gains access to Gs alpha are not known. In the present study, we used subunit-specific antibodies and their corresponding Fab fragments to assess their affects on holotoxin binding to target cells and their immunoreactivity to cell-bound toxin. Our results suggest that CT binds with A1 facing away from the membrane. Our hypothesis is further supported by the ability to assemble active CT on the cell surface of cultured human intestinal and neurotumor cells by the sequential addition of purified B and A subunits. We also observed that when cells containing bound CT were incubated at 37 degrees C, both subunits rapidly became inaccessible to their respective antibodies. We propose that the holotoxin binds with its A subunit facing away from the membrane and must enter the cell in order for A1 to be released, gain access to Gs alpha, and activate adenylylcyclase.
Asunto(s)
Toxina del Cólera/metabolismo , Línea Celular , Membrana Celular/metabolismo , Toxina del Cólera/química , Toxina del Cólera/inmunología , Humanos , Sueros Inmunes/inmunología , Fragmentos Fab de Inmunoglobulinas/inmunología , Cinética , Conformación Proteica , Temperatura , Células Tumorales CultivadasRESUMEN
Cholera toxin (CT) consists of a pentameric B subunit which binds to ganglioside GM1 on the cell surface and an A subunit which activates adenylylcyclase. The latter process involves the reduction of A to the A1 peptide which ADP-ribosylates the stimulatory G protein, Gs of adenylylcyclase. There is a distinct lag phase between toxin binding and activation of adenylylcyclase. Little is known about the events during this lag including where A1 is generated and how it gains access to Gs on the cytoplasmic side of the plasma membrane. We explored the effects of several inhibitors of intracellular trafficking on the response of human SK-N-MC neurotumor and Caco-2 intestinal tumor cells to CT. Whereas chloroquine or monensin had little or no effect on CT stimulation of cyclic AMP accumulation, brefeldin A (BFA) totally inhibited the response to CT in a time- and dose-dependent and reversible manner. BFA was effective when added at the same time as CT and had an IC50 of 30 ng/ml. BFA did not alter cell surface GM1 as cells treated with BFA for 30 min bound as much 125I-CT as control cells. Furthermore, BFA inhibited CT stimulation of GM1-treated rat glioma C6 cells. BFA treatment did not affect beta-adrenergic agonist stimulation of cyclic AMP. In addition, adenylylcyclase was activated by A1 peptide and NAD+ to the same extent in membranes from control and BFA-treated cells, or when BFA was added directly to the assay. Whereas control cells generated small amounts of A1 from bound CT with time, no A1 was detected in BFA-treated cells. BFA treatment did not prevent the internalization of CT but did inhibit its degradation. BFA is known to disrupt the organization of the Golgi complex, resulting in inhibition of protein transport from the endoplasmic reticulum and redistribution of Golgi enzymes to the endoplasmic reticulum. BFA also prevents the formation of non-clathrin-coated vesicles from Golgi membranes and thus vesicular transport between Golgi cisternae. We confirmed that BFA caused the morphological disruption of the Golgi apparatus in Caco-2 cells. The data support a role for a functional Golgi apparatus with its associated vesicular routing in CT action.
Asunto(s)
Adenilil Ciclasas/metabolismo , Toxina del Cólera/farmacología , AMP Cíclico/metabolismo , Ciclopentanos/farmacología , Adenocarcinoma , Animales , Transporte Biológico/efectos de los fármacos , Brefeldino A , Línea Celular , Cloroquina/farmacología , Toxina del Cólera/antagonistas & inhibidores , Toxina del Cólera/metabolismo , Neoplasias del Colon , Activación Enzimática , Glioma , Aparato de Golgi/efectos de los fármacos , Aparato de Golgi/ultraestructura , Humanos , Isoproterenol/farmacología , Cinética , Monensina/farmacología , Micotoxinas/farmacología , Ratas , Factores de Tiempo , Células Tumorales CultivadasAsunto(s)
Toxinas Bacterianas/metabolismo , Toxina del Cólera/metabolismo , Enterotoxinas/metabolismo , Proteínas de Escherichia coli , Gangliósido G(M1) , Gangliósidos/metabolismo , Guanilato Ciclasa , Receptores de Péptidos , Animales , Toxinas Bacterianas/química , Secuencia de Carbohidratos , Toxina del Cólera/química , Enterotoxinas/química , Humanos , Metabolismo de los Lípidos , Lipoproteínas/metabolismo , Datos de Secuencia Molecular , Receptores de Superficie Celular/metabolismo , Receptores de Enterotoxina , Receptores Acoplados a la Guanilato-Ciclasa , Receptores Inmunológicos/metabolismoRESUMEN
Haman SK-N-MC neurotumor cells express both beta(1)-adrenergic and D(1) dopaminergic receptors. Although there were sevenfold more beta(1) than D(1) receptors, maximum stimulation of adenylyl cyclase activity by isoproterenol was only threefold more than that by dopamine. We had shown previously that the pattern of agonist-mediated densensitization was different for the two receptors. To compare the efficiency of the two receptors to couple to the same adenylyl cyclase and to explore the possible role of spare receptors, the cells were exposed to N -ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), which irreversibly alkylates and inactivates catecholamine receptors. Loss of receptor binding activity was dependent on the concentration of EEDQ, D(1) receptors being more sensitive to EEDQ than beta(1) receptors with IC(50) values of 1 and 30 muM, respectively. beta(1) receptors were more sensitive to the irreversible beta-adrenergic antagonist N(8) -bromoacetyl-N(1)-(3'-(4-indolyloxy)-2'-hydroxy-propyl)-[Z]-1,8-diamino-p-menthane (BIM) with an IC(50) of 1 nM. Inactivation of D(1) receptors parallelled the reduction in dopamine-stimulated adenylyl cyclase activity without a shift in K(act), indicating the absence of spare D(1 receptors in SK-N-MC cells. By contrast, there appeared to be spare beta1) receptors as the K(act) shifted before any reduction in isoproterenol-stimulated activity occurred in EEDQ- or BIM-treated cells. Inactivation of 70% of the beta(1) receptors resulted in only a 20% decrease in isoproterenol-stimulated adenylyl cyclase activity, and the remaining beta(1) receptors were as efficient as D(1) receptors in stimulating adenylyl cyclase. In addition, inactivation of the spare beta(1) receptors did not alter the unique pattern of agonist-mediated desensitization. We conclude that human beta(1) and D(1) receptors are equally efficient at stimulating adenylyl cyclase but differ in their mechanisms of agonist-mediated desensitization.
RESUMEN
The fungal metabolite brefeldin A (BFA) is known to disrupt the Golgi apparatus resulting in redistribution of Golgi proteins to the endoplasmic reticulum and inhibition of protein secretion. BFA was found to inhibit protein synthesis in rat glioma C6 cells by up to 70% between 0.1 and 1 microgram/ml. Inhibition was both time-dependent and reversible. BFA inhibited protein synthesis to varying degrees in a number of other cell lines but not in BFA-resistant marsupial kidney cells. The same concentrations of BFA which inhibited protein synthesis, also blocked the inhibitory effects of Pseudomonas exotoxin and ricin on BFA-sensitive cells. BFA, however, was unable to block the inhibition of protein synthesis by the toxins in the resistant marsupial kidney cells.